PROF Overview

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is11.67 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Profound Medical Corp revenue for the last quarter amounts to 5.98M USD, increased 43.13

Profound Medical Corp. EPS for the last quarter amounts to -0.27 USD, increased 42.11

Profound Medical Corp (PROF) has 131 emplpoyees as of March 25 2026.

Today PROF has the market capitalization of 186.91M USD.